Teva (TEVA) and Antares (AIS) Announce FDA Approval of Needle-Free Injector for Tev-Tropin(R)
Down)
Earlier this morning, Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) and its partner, Antares Pharma, Inc. (Amex: AIS) today announced the approval of a Supplemental New Drug Application, which added "needle-free injection" to its Tev-Tropin(R) [somatropin for injection] brand human growth hormone drug label. Teva will market the Antares needle-free device as the Tev-Tropin Tjet Injector system.
Shares of Antares have spiked about 60% on the news today. The stock is seeing extremely heavy volume: already has more than 9.5 million shares, which compares to its 30-day average volume of 157,000 shares.
Shares of Antares have spiked about 60% on the news today. The stock is seeing extremely heavy volume: already has more than 9.5 million shares, which compares to its 30-day average volume of 157,000 shares.
You May Also Be Interested In
- Teva Provides Updated 2012 Non-GAAP Financial Outlook; Updated 2012 Non-GAAP Diluted EPS of $5.30 to $5.40
- Barclays Maintains an 'Equalweight' on Teva Pharma (TEVA); Adjusting Estimates After Business Update
- Proctor & Gamble (PG) To Change 'Tide Pods' Design So Kids Don't Eat Them
Create E-mail Alert Related Categories
Corporate NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
